中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 12
Dec.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(12): 2959-2964

Evaluation of cholestatic liver disease animal model based on clinical syndrome characteristics of integrated traditional Chinese and Western medicine

DOI: 10.3969/j.issn.1001-5256.2023.12.031
  • a.

    The First Clinical Medical College, Henan University of Chinese Medicine，Zhengzhou 450046，China

  • b.

    School of Pharmacy，Henan University of Chinese Medicine，Zhengzhou 450046，China

Research funding:

National Natural Science Foundation Project (82074340);

Henan Science and Technology Innovation Talent Program-Outstanding Youth project (154100510020);

Henan University Science and Technology Innovation Team support project (16IRTSTHN023)

More Information
  • Corresponding author: ZHU Pingsheng， zhupingsheng@126.com （ORCID： 0009-0002-1678-392X）
  • Received Date: 2023-02-24
  • Accepted Date: 2023-03-27
  • Published Date: 2023-12-12
    Abstract
  • Cholestatic liver disease is a common disease of the hepatobiliary system. Its etiology and pathogenesis are complex. The establishment of an appropriate animal model of cholestatic liver disease is the basis for further study of its pathogenesis and prevention. This study summarized the existing modeling methods， mechanisms， and characteristics of this model， and analyzed its alignment with the clinical disease and syndrome characteristics of integrated traditional Chinese and Western medicine based on the modern clinical diagnostic criteria and traditional Chinese medicine syndrome characteristics of cholestatic liver disease， so as to provide a reference for establishing standard animal models and evaluation methods for cholestatic liver disease that accord better with the clinical practice of integrated traditional Chinese and Western medicine.

     

    • FullText(HTML)
  • loading
    • References(38)
  • [1]
    YANG JY, YANG H, DAI Y, et al. Study on treatment of cholestatic liver disease based on“dampness, heat and blood stasis”[J]. Chin J Basic Med Tradit Chin Med, 2022, 28( 6): 1009- 1013, 1018. DOI: 10.19945/j.cnki.issn.1006-3250.2022.06.013.

    杨家越, 杨恒, 代耀, 等. 基于“湿、热、瘀”论治胆汁淤积性肝病的研究[J]. 中国中医基础医学杂志, 2022, 28( 6): 1009- 1013,1018. DOI: 10.19945/j.cnki.issn.1006-3250.2022.06.013.
    [2]
    LI GD, YANG JY, MA XH, et al. Therapeutic mechanism of qingekasen granules in treatment of intrahepatic cholestasis rats[J]. World Sci Technol Modern Tradit Chin Med, 2022, 24( 10): 4038- 4046. DOI: 10.11842/wst.20220103002.

    李国栋, 杨金玉, 马小华, 等. 清热卡森颗粒对肝内胆汁淤积大鼠模型的治疗作用及机制研究[J]. 世界科学技术-中医药现代化, 2022, 24( 10): 4038- 4046. DOI: 10.11842/wst.20220103002.
    [3]
    WU H, CHEN C, ZIANI S, et al. Fibrotic events in the progression of cholestatic liver disease[J]. Cells, 2021, 10( 5): 1107. DOI: 10.3390/cells10051107.
    [4]
    YAO J, YAN J, WU J, et al. Predicting target genes of San-Huang-Chai-Zhu formula in treating anit-induced acute intrahepatic cholestasis rat model via bioinformatics analysis combined with experimental validation[J]. Evid Based Complement Alternat Med, 2021, 2021: 5320445. DOI: 10.1155/2021/5320445.
    [5]
    XIE W, CAO Y, XU M, et al. Prognostic significance of elevated cholestatic enzymes for fibrosis and hepatocellular carcinoma in hospital discharged chronic viral hepatitis patients[J]. Sci Rep, 2017, 7( 1): 10289. DOI: 10.1038/s41598-017-11111-5.
    [6]
    XU D, YIN MJ, WANG YM, et al. Research progress in the regulation of FXR-CYP7A1 axis in cholestatic liver disease[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31( 5): 470- 473. DOI: 10.3969/j.issn.1005-0264.2021.05.025.

    徐懂, 尹美君, 王钰铭, 等. FXR-CYP7A1轴在胆汁淤积性肝病中的调控研究进展[J]. 中西医结合肝病杂志, 2021, 31( 5): 470- 473. DOI: 10.3969/j.issn.1005-0264.2021.05.025.
    [7]
    LI WH, ZHANG GX, NIE W, et al. Therapeutic effect of Modified Yinchenhao Tang on cholestatic liver disease in rats[J]. Chin J Exp Med Formul, 2020, 26( 4): 29- 34. DOI: 10.13422/j.cnki.syfjx.20200436.

    李婉华, 张桂贤, 聂卫, 等. 加味茵陈蒿汤对大鼠胆汁淤积性肝病的治疗作用[J]. 中国实验方剂学杂志, 2020, 26( 4): 29- 34. DOI: 10.13422/j.cnki.syfjx.20200436.
    [8]
    CHIANG J, FERRELL JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318( 3): G554- G573. DOI: 10.1152/ajpgi.00223.2019.
    [9]
    YUAN RL, ZHANG YW, SHEN JY, et al. Research progress in the effect and mechanism of medicinal plants derived terpenoids on cholestatic liver injury[J]. Central South Pharm, 2022, 20( 4): 877- 887. DOI: 10.7539/j.issn.1672-2981.2022.04.024.

    袁若兰, 张议文, 沈佳妍, 等. 药用植物中萜类化合物改善胆汁淤积性肝损伤的作用及机制研究进展[J]. 中南药学, 2022, 20( 4): 877- 887. DOI: 10.7539/j.issn.1672-2981.2022.04.024.
    [10]
    LI J, ZHENG KY, ZHANG BB. Mechanism of action of bile acid metabolism in regulating cholestatic liver disease and the research and development of drugs[J]. J Clin Hepatol, 2021, 37( 10): 2482- 2487. DOI: 10.3969/j.issn.1001-5256.2021.10.048.

    李静, 郑葵阳, 张蓓蓓. 胆汁酸代谢调节胆汁淤积性肝病的作用机制及药物研发[J]. 临床肝胆病杂志, 2021, 37( 10): 2482- 2487. DOI: 10.3969/j.issn.1001-5256.2021.10.048.
    [11]
    ZHAO Y, LIU FQ, TIAN S, et al. Research progress in mechanism of traditional Chinese medicine in treatment of cholestatic liver disease[J]. Drug Eval Res, 2022, 45( 2): 375- 381. DOI: 10.7501/j.issn.1674-6376.2022.02.025.

    赵阳, 刘凡琪, 田爽, 等. 中药治疗胆汁淤积性肝病作用机制的研究进展[J]. 药物评价研究, 2022, 45( 2): 375- 381. DOI: 10.7501/j.issn.1674-6376.2022.02.025.
    [12]
    JIRIMU BT, XIE GM, FAN N, et al. Research on therapeutic mechanism of Canhuang tablets on jaundiced rats induced by ANIT[J]. Chin J Exp Med Formul, 2020, 26( 17): 64- 69. DOI: 10.13422/j.cnki.syfjx.20201050.

    吉日木 巴图, 谢国明, 范娜, 等. 残黄片对ANIT诱导黄疸模型大鼠的退黄作用机制分析[J]. 中国实验方剂学杂志, 2020, 26( 17): 64- 69. DOI: 10.13422/j.cnki.syfjx.20201050.
    [13]
    Chinese Society of Hepatology, Chinese Medical Association. Guideline on the management of cholestasis liver disease(2021)[J]. J Clin Hepatol, 2022, 38( 1): 62- 69.

    中华医学会肝病学分会. 胆汁淤积性肝病管理指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 62- 69.
    [14]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and treatment of cholestasis liver diseases(2015)[J]. J Clin Hepatol, 2015, 31( 12): 1989- 1999.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31( 12): 1989- 1999.
    [15]
    TIAN S, CAO LH, MIAO MS, et al. A new method for the evaluation of animal models used in traditional Chinese Medicine based on the clinical characteristics of Chinese and Western medicine[J]. Pharmacol Clin Chin Mater Med, 2017, 33( 6): 165- 169.

    田硕, 曹利华, 苗明三, 等. 基于临床中西医病症特点的中医药动物模型评价新方法[J]. 中药药理与临床, 2017, 33( 6): 165- 169.
    [16]
    WU MH, SHI Y. Internal medicine of Chinese medicine[M]. Beijing: China Medical Science Press, 2021.

    吴勉华, 石岩. 中医内科学[M]. 北京: 中国中医药出版社, 2021.
    [17]
    Basis Diagnostic, Classification of Syndrome and Evaluation of Curative Effect of jaundice-Standard of TCM Industry of the People’s Republic of China(ZY/T 001. 1- 94)[J]. J Liaoning Univ Tradit Chin Med, 2016, 18( 5): 248.

    黄疸的诊断依据、证候分类、疗效评定——中华人民共和国中医药行业标准《中医内科病证诊断疗效标准》(ZY/T 001. 1- 94)[J]. 辽宁中医药大学学报, 2016, 18( 5): 248.
    [18]
    XIE YH, TANG B, FAN CX, et al. Alpha-ketoglutarate alleviates cholestatic liver injury in mice[J]. J Army Med Univ, 2022, 44( 13): 1322- 1329. DOI: 10.16016/j.2097-0927.202112271.

    谢雨虹, 唐波, 范崇熙, 等. α-酮戊二酸对小鼠胆汁淤积性肝损伤的缓解作用[J]. 陆军军医大学学报, 2022, 44( 13): 1322- 1329. DOI: 10.16016/j.2097-0927.202112271.
    [19]
    LEI YY, HAO XJ, WANG YN, et al. Protective effects on cholestatic liver injury in rats and acute toxicity of Huanggan decoctions[J]. Phar Clin Res, 2023, 31( 3): 212- 216,269. DOI: 10.13664/j.cnki.pcr.2023.03.020.

    雷亚亚, 郝秀娟, 王亚楠, 等. 黄肝煎液对胆汁淤积性肝损伤大鼠的保护作用及急性毒性研究[J]. 药学与临床研究, 2023, 31( 3): 212- 216, 269. DOI: 10.13664/j.cnki.pcr.2023.03.020.
    [20]
    ZHANG GQ, WEI YH, WEN YJ, et al. Effect of water extract of fructus gardenia on sulfated bile acids in rats with estrogen-induced cholestasis and its mechanism[J]. Chin Pharm J, 2020, 55( 20): 1680- 1685. DOI: 10.11669/cpj.2020.20.005.

    张国强, 魏玉辉, 文苑洁, 等. 栀子水提物对雌激素诱导的胆汁淤积大鼠中硫酸化胆酸盐的影响及机制研究[J]. 中国药学杂志, 2020, 55( 20): 1680- 1685. DOI: 10.11669/cpj.2020.20.005.
    [21]
    ZHANG G, CHEN L, CHEN J, et al. Research on characteristics of liver injury induced by rifampicin in mice[J]. J Reg Anat Oper Surg, 2017, 26( 4): 244- 247.

    张刚, 陈磊, 陈静, 等. 不同剂量利福平致小鼠肝损伤特点的研究[J]. 局解手术学杂志, 2017, 26( 4): 244- 247.
    [22]
    ZHANG B, TAN RX, HUANG ZY, et al. Study on therapeutic effect of MMI-0100 against DDC-induced cholestatic liver injury[J]. Chin J Mod Appl Pharm, 2022, 39( 13): 1692- 1697. DOI: 10.13748/j.cnki.issn1007-7693.2022.13.005.

    张波, 谈仁秀, 黄芝月, 等. MMI-0100对DDC诱导的胆汁淤积性肝损伤的治疗作用研究[J]. 中国现代应用药学, 2022, 39( 13): 1692- 1697. DOI: 10.13748/j.cnki.issn1007-7693.2022.13.005.
    [23]
    GAO Y, CHAI J, LI SX, et al. Protective effect of alcohol extract of Swertia mussotii Franch on lipopolysaccharideinduced cholestatic liver damage in rats[J]. J Third Milit Med Univ, 2014, 36( 8): 769- 773. DOI: 10.16016/j.1000-5404.2014.08.006.

    高宇, 柴进, 李绍雪, 等. 川西獐牙菜醇提物对内毒素所致大鼠胆汁淤积性肝损伤的保护作用[J]. 第三军医大学学报, 2014, 36( 8): 769- 773. DOI: 10.16016/j.1000-5404.2014.08.006.
    [24]
    SONG DJ, DAI MY, HUA HY, et al. Protection of chlorogenic acid aganist cholestatic liver injury induced by lithocholicacid and the underlying mechanism[J]. Acta Nutrimenta Sinica, 2017, 39( 3): 280- 286,293. DOI: 10.13325/j.cnki.acta.nutr.sin.2017.03.012.

    宋丹军, 代曼云, 华慧英, 等. 绿原酸抗石胆酸胆汁淤积模型肝损伤的作用与机制研究[J]. 营养学报, 2017, 39( 3): 280- 286,293. DOI: 10.13325/j.cnki.acta.nutr.sin.2017.03.012.
    [25]
    ZHANG L, ZHAN J, WU BH, et al. TNF-α Study on drug-induced liver injury in rats induced by chlorpromazine[J]. Chin Hepatol, 2014, 19( 10): 768- 771. DOI: 10.14000/j.cnki.issn.1008-1704.2014.10.013.

    张蕾, 詹俊, 伍百贺, 等. TNF-α与氯丙嗪所致大鼠药物性肝损伤的研究[J]. 肝脏, 2014, 19( 10): 768- 771. DOI: 10.14000/j.cnki.issn.1008-1704.2014.10.013.
    [26]
    SUN XD. Oxidative damage of liver and myocardium induced by TPN and the mechanism of MRPL35/ROS/JNK/NF-κB pathway in PNAC[D]. Chongqing: Army Medical University, 2022.

    孙晓东. TPN致肝脏和心肌氧化损伤及MRPL35/ROS/JNK/NF-κB通路在PNAC中的效应机制研究[D]. 重庆: 中国人民解放军陆军军医大学, 2022.
    [27]
    van GOLEN RF, OLTHOF PB, de HAAN LR, et al. The pathophysiology of human obstructive cholestasis is mimicked in cholestatic Gold Syrian hamsters[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864( 3): 942- 951. DOI: 10.1016/j.bbadis.2017.11.022.
    [28]
    ZHI TW, LIU CH. Effect of geniposidic acid on bile duct ligation-induced cholestasis mice through modulation of farnesoid X receptor[J]. Tradit Chin Drug Res Clin Pharmacol, 2022, 33( 12): 1606- 1613. DOI: 10.19378/j.issn.1003-9783.2022.12.003.

    支廷威, 刘昌辉. 京尼平苷酸通过调控法尼醇X受体对胆管结扎诱导的胆汁淤积小鼠的影响[J]. 中药新药与临床药理, 2022, 33( 12): 1606- 1613. DOI: 10.19378/j.issn.1003-9783.2022.12.003.
    [29]
    HU GW, XUE JH, BAI Y, et al. A comparative study suitable for imaging studies of liver fibrosis in rats[J]. J Gannan Med Univ, 2018, 38( 5): 422- 425, 435. DOI: 10.3969/j.issn.1001-5779.2018.05.002.

    胡根文, 薛进华, 柏燕, 等. 两种大鼠肝纤维化模型的病理特点及影像学研究[J]. 赣南医学院学报, 2018, 38( 5): 422- 425, 435. DOI: 10.3969/j.issn.1001-5779.2018.05.002.
    [30]
    DU Z, QIU JN, GUO Z, et al. Efficacy/hepatoxicity mechanism of geniposide with different doses and courses in the regulation of chronic cholestasis[J]. China J Tradit Chin Med Pharm, 2022, 37( 7): 4048- 4053.

    杜曾, 邱剑楠, 郭真, 等. 不同剂量和疗程栀子苷调控慢性胆汁淤积的疗效/肝毒性效应机制[J]. 中华中医药杂志, 2022, 37( 7): 4048- 4053.
    [31]
    WU HF, ZHANG FL, DENG XY, et al. Mechanism of paeoniflorin in improving α-isothiocyanate induced cholestasis by regulating intestinal flora in rats[J]. Chin Tradit Herb Drug, 2022, 53( 22): 7091- 7101. DOI: 10.7501/j.issn.0253-2670.2022.22.012.

    吴和霏, 章方玲, 邓昕雨, 等. 芍药苷通过调控肠道菌群改善α-异硫氰酸酯诱导胆汁淤积大鼠的作用机制研究[J]. 中草药, 2022, 53( 22): 7091- 7101. DOI: 10.7501/j.issn.0253-2670.2022.22.012.
    [32]
    QIU J, YAN J, LIU W, et al. Metabolomics analysis delineates the therapeutic effects of Huangqi decoction and astragalosides on α-naphthylisothiocyanate(ANIT)-induced cholestasis in rats[J]. J Ethnopharmacol, 2021, 268: 113658. DOI: 10.1016/j.jep.2020.113658.
    [33]
    WANG YX, WANG Q, TIAN Y. Mechanisms of chemicals in establishing animal models of liver injury[J]. Chin J Comp Med, 2022, 32( 10): 109- 114. DOI: 10.3969/j.issn.1671-7856.2022.10.014.

    王雨欣, 王倩, 田颖. 不同化学物质建立肝损伤动物模型的作用机制[J]. 中国比较医学杂志, 2022, 32( 10): 109- 114. DOI: 10.3969/j.issn.1671-7856.2022.10.014.
    [34]
    NONG C, ZOU M, XUE R, et al. The role of invariant natural killer T cells in experimental xenobiotic-induced cholestatic hepatotoxicity[J]. Biomed Pharmacother, 2020, 122: 109579. DOI: 10.1016/j.biopha.2019.109579.
    [35]
    DU LN, YANG Y. Establishment and application of animal models of cholestasis[J]. J Clin Hepatol, 2019, 35( 2): 444- 447. DOI: 10.3969/j.issn.1001-5256.2019.02.046.

    杜丽娜, 杨燕. 胆汁淤积动物模型的构建及应用前景[J]. 临床肝胆病杂志, 2019, 35( 2): 444- 447. DOI: 10.3969/j.issn.1001-5256.2019.02.046.
    [36]
    ZHU PS, WANG B, LONG AH. Effect of different classic formulas on the liver and renal function of extrahepatic cholestasis in rats[J]. J Tradit Chin Med, 2011, 52( 4): 319- 321, 348. DOI: 10.13288/j.11-2166/r.2011.04.030.

    朱平生, 王兵, 龙爱华. 不同经典方剂对肝外胆汁淤积大鼠肝肾功能的影响[J]. 中医杂志, 2011, 52( 4): 319- 321, 348. DOI: 10.13288/j.11-2166/r.2011.04.030.
    [37]
    ZHU PS, LONG AH, WANG B. Effect of different classic formulas on the liver and renal function of intrahepatic cholestasis in rats[J]. Chin J Exp Med Formul, 2011, 17( 5): 200- 201. DOI: 10.13422/j.cnki.syfjx.2011.05.015.

    朱平生, 龙爱华, 王兵. 不同经典方剂对肝内胆汁淤积大鼠肝肾功能的影响[J]. 中国实验方剂学杂志, 2011, 17( 5): 200- 201. DOI: 10.13422/j.cnki.syfjx.2011.05.015.
    [38]
    WU HB, SHE SF, LAN SY. Effect of Yinzhihuang Injection on expression of NTCP and BSEP in dampness-heat syndrome of intrahepatic cholestasis[J]. Lishizhen Med Mater Med Res, 2015, 26( 10): 2318- 2321. DOI: 10.3969/j.issn.1008-0805.2015.10.006.

    吴海滨, 佘世锋, 兰绍阳. 茵栀黄注射液对肝内胆汁淤积湿热证大鼠NTCP、BSEP表达的影响[J]. 时珍国医国药, 2015, 26( 10): 2318- 2321. DOI: 10.3969/j.issn.1008-0805.2015.10.006.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (330) PDF downloads(22) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return